Merck's Protease Inhibitor Franchise Growth Tied To MK-994A Combination
Executive Summary
Merck hopes to expand its HIV protease inhibitor franchise with a new combination formulation of Crixivan and MK-994, Merck Research Laboratories President Edward Scolnick, MD, said at a Dec. 9 analyst briefing in Whitehouse Station, N.J.